Cogent Biosciences, Inc. reported $7.9M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $7.9M (to Q4 2020). Net income: −$377M, trailing twelve months to Q2 2026. Free cash flow: −$309M, trailing twelve months to Q2 2026. EPS: −$2.16, trailing twelve months to Q2 2026.

COGTCogent Biosciences, Inc.

Healthcare

$31.02+159% 1Y

$31.02

$12.5152 weeks$42.84

COGT as reported

Cogent Biosciences, Inc. reported $7.9M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$7.9M

Revenue, trailing twelve months · to Q4 2020 · every figure below is as filed, with no scoring applied

Net income: −$377M
Net income · +33% year on year · trailing twelve months to Q2 2026
Free cash flow: −$309M
Free cash flow · +32% year on year · trailing twelve months to Q2 2026
EPS: −$2.16
EPS · +4.3% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for COGT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$7.9M	n/a	Q4 2020 · 22 quarters behind
Net income	−$377M	+33%	Q2 2026
EPS	−$2.16	+4.3%	Q2 2026
Operating margin	−4952%	n/a	Q3 2020 · 23 quarters behind
Net margin	−4373%	n/a	Q3 2020 · 23 quarters behind
ROE	−70%	n/a	Q2 2026
ROA	−47%	n/a	Q2 2026
ROIC	708%	n/a	Q2 2026
Free cash flow	−$309M	+32%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.